Inhaled drug tested for long-term safety in lung-related high blood pressure

NCT ID NCT07234032

Recruiting now Disease control Sponsor: Insmed Incorporated Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This phase 3 study tests the long-term safety of an inhaled drug called treprostinil palmitil for people with pulmonary hypertension caused by interstitial lung disease. About 344 adults who completed an earlier trial will take the drug for up to 2 years. Researchers will track side effects and measure changes in walking distance and lung function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Treprostinil palmitil inhalation powder (TPIP)
What this could lead to: If successful, this could confirm a safe long-term treatment option to help manage pulmonary hypertension in people with interstitial lung disease.
What could go wrong: This is an extension study focused on safety, not on proving the drug works. It only includes people who already completed an earlier trial, so results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

interstitial lung disease pulmonary hypertension pulmonary hypertension owing to lung disease and/or hypoxia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTERSTITIAL LUNG DISEASE PULMONARY HYPERTENSION

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

ESP001
NOT_YET_RECRUITING

Seville, 41009, Spain
ESP003
NOT_YET_RECRUITING

Madrid, 28046, Spain
ESP006
NOT_YET_RECRUITING

Madrid, 28041, Spain
JPN004
NOT_YET_RECRUITING

Narita, Chiba, 286-8520, Japan
KOR001
NOT_YET_RECRUITING

Seoul, 3080, South Korea
KOR006
NOT_YET_RECRUITING

Seoul, 6351, South Korea
TWN003
NOT_YET_RECRUITING

Hsinchu, 30059, Taiwan
USA003
RECRUITING

Bend, Oregon, 97701, United States
USA006
RECRUITING

Naples, Florida, 34102, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.